The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A

European Neuropsychopharmacology

Volumn 16, Issue 3, 2006, Pages 178-186

  Haduch, A ^a   Wojcikowski J ^a   Daniel, W A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antidepressants; Chronic treatment; CYP3A; Direct effect; One day treatment; Rat

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TESTOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REGULATION; LIVER MICROSOME; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BLOTTING, WESTERN; CYTOCHROME P-450 CYP3A; HUMANS; KINETICS; MALE; MICROSOMES, LIVER; PROTEIN BINDING; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; TESTOSTERONE;

EID: 33644825809     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2005.08.004     Document Type: Article

References (51)

1. M. Anderson, S.M. Bandiera, T.K.H. Chang, and G.D. Bellward Effect of androgen administration during puberty on hepatic CYP2C11, CYP3A, and CYP2A1 expression in adult female rats Drug Metab. Dispos. 26 1998 1031 1038
2. C. Bensoussan, M. Delaforge, and D. Mansuy Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs Biochem. Pharmacol. 49 1995 591 602
3. K. Brøsen, E. Skjelbo, B.B. Rasmussen, H.E. Poulsen, and S. Loft Fluvoxamine is a potent inhibitor of cytochrome P4501A2 Biochem. Pharmacol. 45 1993 1211 1214
4. O. Burk, and L. Wojnowski Cytochrome P450 3A and their regulation Naunyn-Schmiedeberg's Arch. Pharmacol. 369 2004 105 124
5. H.K. Crewe, M.S. Lennard, G.T. Tucker, F.R. Woods, and R.E. Haddock The effect of selective re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes Br. J. Clin. Pharmacol. 34 1992 262 265
6. M.L. Dahl, G. Voortman, C. Alm, C.E. Elwin, L. Delbressine, R. Vos, J.J.P. Bogaards, L. Bertilsson, M.E.G. Moonen, and F.M. Kaspersen In vitro and in vitro studies on the disposition of mirtazapine in humans Clin. Drug Investig. 13 1997 37 46
7. W. Daniel, and K.J. Netter Alteration of cytochrome P-450 by prolonged administration of imipramine and/or lithium to rats Naunyn-Schmiedeberg's Arch. Pharmacol. 342 1992 234 240
8. W. Daniel, A. Adamus, M. Melzacka, J. Szymura, and J. Vetulani Cerebral pharmacokinetics of imipramine in rats after single and multiple dosages Naunyn-Schmiedeberg's Arch. Pharmacol. 317 1981 209 213
9. W.A. Daniel, M. Syrek, A. Haduch, and J. Wójcikowski The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vitro and in vitro studies Exp. Toxic. Pathol. 51 1999 309 314
10. W.A. Daniel, M. Syrek, and J. Wójcikowski The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat Eur. Neuropsychopharmacol. 9 1999 337 344
11. W.A. Daniel, M. Syrek, A. Haduch, and J. Wójcikowski Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants Br. J. Pharmacol. 131 2000 287 295
12. W.A. Daniel, M. Syrek, A. Haduch, and J. Wójcikowski The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat J. Pharm. Pharmacol. 53 2001 449 461
13. W.A. Daniel, A. Haduch, and J. Wójcikowski Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants J. Pharm. Pharmacol. 54 2002 1545 1552
14. K. Debri, A.R. Boobis, D.S. Davies, and R.J. Edwards Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues Biochem. Pharmacol. 50 1995 2047 2056
15. G.G. Gibson, N.J. Plant, K.E. Swales, A. Ayrton, and W. El-Sankary Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man Xenobiotica 32 2002 165 206
16. J. Hall, C.A. Naranjo, B.A. Sproule, and N. Herrmann Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine J. Clin. Psychopharmacol. 23 2003 349 357
17. P. Honkakoski, and M. Negishi Regulation of cytochrome P450 (CYP) genes by nuclear receptors Biochem. J. 347 2000 321 337
18. P. Honkakoski, I. Jaaskelainen, M. Kortelahti, and A. Urtti A novel drug-regulated gene expression system based on the nuclear receptor constitutive androstane receptor (CAR) Pharmacol. Res. 18 2001 146 150
19. U. Jeppesen, L.F. Gram, K. Vistisen, S. Loft, H.E. Poulsen, and K. Brøsen Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine Eur. J. Clin. Pharmacol. 51 1996 73 78
20. A. Jus, J. Gautier, A. Villeneuvue, K. Jus, P. Pires, N. Gagnon-Binette, and C. Fortin Pharmacokinetic interaction between amitriptyline and neuroleptics Neuropsychobiology 4 1978 305 310
21. M. Komori, and Y. Oda A major glucocorticoid-inducible P450 in rat liver is not P450 3A1 J. Biochem. (Tokyo) 116 1994 114 120
22. C. Liddle, B.J. Goodwin, J. George, M. Tapner, and G.C. Farreli Separate and interactive regulation of cytochrome P450 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes J. Clin. Endocrinol. Metab. 83 1998 2411 2416
23. S. Loga, S. Curry, and M. Lader Interaction of chloropromazine and nortriptyline in patients with schizophrenia Clin. Pharmacokinet. 6 1981 454 462
24. Y. Masubuchi, CH. Takahashii, N. Fujio, T. Horie, T. Suzuki, S. Imaoka, Y. Funae, and S. Narimatsu Inhibition and induction of cytochrome P450 isoenzymes after repetitive administration of imipramine in rats Drug Metab. Dispos. 23 1995 999 1003
25. C.M. McNeil, and M. Murray Inhibition of microsomal cytochromes P450 in rat liver by the tricycle antidepressant drug desipramine and its primary oxidized metabolites Biochem. Pharmacol. 51 1996 15 20
26. M. Murray, and S.L. Field Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants Biochem. Pharmacol. 43 1992 2065 2071
27. M. Murray, and K. Murray Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines Xenobiotica 33 2003 973 987
28. J.M. Pascussi, L. Drocourt, J.M. Fabre, P. Maurel, and M.J. Vilarem Dexamethasone induces pregnane X receptor and retinoid X receptor-α expression in human hepatocytes: synergistic increaseof CYP3A4 induction by pregnane X receptor Mol. Pharmacol. 58 2000 361 372
29. J.M. Pascussi, S. Gerbal-Chaloin, J.M. Fabre, P. Maurel, and M.J. Vilarem Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation Mol. Pharmacol. 58 2000 1441 1450
30. J.M. Pascussi, S. Gerbal-Chaloin, L. Pichard-Garcia, M. Daujat, J.M. Fabre, P. Maurel, and M.J. Vilarem Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes Biochem. Biophys. Res. Commun. 274 2000 707 713
31. J.M. Pascussi, S. Gerbal-Chaloin, L. Drocourt, J.M. Fabre, P. Maurel, and M.J. Vilarem The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors Biochim. Biophys. Acta. 1619 2003 243 253
32. S. Preskorn Clinically relevant pharmacology of selective serotonin reuptake inhibitors Clin. Pharmacokinet. 32 Suppl. 1 1997 1 21
33. L.C. Quatrochi, and P.S. Guzelian CYP3A regulation: from pharmacology to nuclear receptors Drug Metab. Dispos. 29 2001 615 622
34. B.J. Ring, S.N. Binkley, N. Roskos, and S.A. Wrighton Effects of fluoxetine, sertraline and desmethylsertraline on human CYP3A catalyzed 1′-hydroxy midazolam formation in vitro J. Pharmacol. Exp. Ther. 275 1995 1131 1135
35. M.L. Schrag, and L.C. Wienkers Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains Arch. Biochem. Biophys. 391 2001 49 55
36. J.G. Shin, J.Y. Park, M.J. Kim, J.H. Shon, Y.R. Yoon, I.J. Cha, S.S. Lee, S.W. Oh, S.W. Kim, and D.A. Flockhart Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin Drug Metab. Dispos. 30 2002 1102 1107
37. A. Skjelbo, and K. Brøsen Inhibitors of imipramine metabolism by human liver microsomes Br. J. Clin. Pharmacol. 34 1992 256 261
38. A.J. Sonderfan, M.P. Arlotto, D.R. Dutton, S.K. McMillen, and A. Parkonson Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450 Arch. Biochem. Biophys. 255 1987 27 41
39. B.A. Sproule, C.A. Naranjo, K.E. Brenmer, and P.C. Hassan Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence Clin. Pharmacokinet. 33 1997 454 471
40. J.A. Sunman, R.L. Hawke, E.L. LeCluyse, and A.D. Kashuba Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes Drug Metab. Dispos. 32 2004 359 363
41. M. Syrek, J. Wójcikowski, and W.A. Daniel Promazine pharmacokinetics during concurrent treatment with tricyclic antidepressants Pol. J. Pharmacol. 49 1997 453 462
42. L.L. von Moltke, D.J. Greenblatt, J. Schmider, S.X. Duan, C.E. Wright, J.S. Harmatz, and R.I. Shader Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents J. Clin. Pharmacol. 36 1996 783 791
43. L.L. von Moltke, D.J. Greenblat, B.W. Granda, S.X. Duan, J.M. Grassi, J. Schmider, J.S. Harmatz, and R.J. Shader Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions Psychopharmacology 145 1999 113 122
44. H. Wang, H. Kawashima, and H.W. Strobel cDNA cloning of a novel CYP3A from rat brain Biochem. Biophys. Res. Commun. 221 1996 157 162
45. R.W. Wang, D.J. Newton, N. Liu, W.M. Atkins, and A.Y. Lu Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent Drug Metab. Dispos. 28 2000 360 366
46. S.J. Warrington Clinical implications of the pharmacology of serotonin reuptake inhibitors Int. Clin. Psychopharmacol. 7 1992 13 19
47. P.B. Watkins Drug metabolism by cytochrome P450 in the liver and small bowel Gastroenterol. Clin. North Am. 21 1992 511 526
48. D.J. Waxman, P.A. Ram, N.A. Pampori, and B.H. Shapiro Growth hormone regulation of male-specific rat liver P450s 2A2 and 3A2: induction by intermittent growth hormone pulses in male but not female rats rendered growth hormone deficient by neonatal monosodium glutamate Mol. Pharmacol. 48 1995 790 797
49. J. Wójcikowski, and W.A. Daniel Thioridazine-fluoxetine interaction at the level of the distribution process in vivo Pol. J. Pharmacol. 54 2002 647 654
50. H. Zhang, E. Le Culyse, L. Liu, M. Hu, L. Matoney, W. Zhu, and B. Yan Rat pregnane X receptor: molecular cloning, tissue distribution and xenobiotic regulation Arch. Biochem. Biophys. 368 1999 14 22
51. X.J. Zhao, and T. Ishizaki The in vitro hepatic metabolism of quinidine in mice, rats and dogs: comparison with human liver microsomes J. Pharmacol. Exp. Ther. 283 1997 1168 1176